Phase 1, Double Blind, Randomized, Parallel-group, Single-dose, Comparative Pharmacokinetic, Safety, Tolerability Study of Exemptia (Adalimumab) injection, solution for subcutaneous use (40 mg/0.8 ml.) with HumiraÂ® (Adalimumab) injection, solution for subcutaneous use(40mg/0.8ml) administered to healthy subjects.
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Rus Biopharm
- 06 Mar 2017 Status changed from recruiting to completed.
- 31 Aug 2016 New trial record